Table 2.

Factors available to assess the efficacy of HLA antibody desensitization.

Pre-Transplant	Post-Transplant
Change in HLA antibodies • Solid-phase assay: antibody MFI, change in reactivity pattern, C1q status, titer • Flow cytometric crossmatch: B and T cell positive or negative	Engraftment • Days until chimerism (CD3+ and CD33+) Disease relapse Graft Versus Host Disease • Acute or chronic Clinical outcome • Non-relapse mortality • Opportunistic infection • Survival (overall and progression-free)